Safety of amisulpride in combination with antidepressants under common clinical practice conditions

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 2, 2011, Pages 157-161

  Ceskova, Eva ^a   Suchopar, Josef ^b   Priborska, Zuzana ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b INFOPHARM as   (Czech Republic)

^c Sanofi aventis sro   (Czech Republic)

Author keywords

adverse events; amisulpride; combination of antidepressants; Depression; selective serotonin reuptake inhibitors

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DIBENZEPIN; DOSULEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TIANEPTINE; TRAZODONE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; CLINICAL PRACTICE; CONSTIPATION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MASTALGIA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE;

EID: 79955786950     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2010.544744     Document Type: Article

References (14)

1. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9. (Pubitemid 44192421)
2. Gershon AA, Vishne T, Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007;61:145-53. (Pubitemid 46072787)
3. De Lima MSW, Hotopf M. Benefit and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence. Drug Saf 2003;26:55-64. (Pubitemid 36092276)
4. Ceskova E. Deniban in the treatment of dysthymia. Ces Slov Psychiatr 2007;103:73-9. (Pubitemid 46595943)
5. Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002 63:685-93.
6. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr 2009;14:71-3.
7. Lecrubier Y, Bahk Won-Myong, De Matos J, Briley M. The management of depression: An international naturalistic survey. Int J Clin Pract 2008 12:285-91.
8. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry 2007;68(Suppl 10):11-17. (Pubitemid 47507832)
9. Noble S, Benfield P. Amisulpride; a review of its clinical potential in dysthymia. CNS Drugs 1999;12:471-83. (Pubitemid 30020132)
10. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian(R): a review of 11 clinical studies. Int Clin Psychopharmacol 1999;14:209-18. (Pubitemid 29358987)
11. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacology 2006;16:391-402. (Pubitemid 43975351)
12. Leucht S, Busch R, Haman J, Kissling W, Kane JM. Early onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005; 57:1543-9. (Pubitemid 40805384)
13. Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy J Affect Disord 2005;89:1-11. (Pubitemid 41740829)
14. Bllier P, Ward HE, Trembley P, Laberge L, Hébert C, Bergeron R. Combination af antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281-8.